Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$71.70 USD

71.70
537,198

+1.33 (1.89%)

Updated Nov 4, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up

by Zacks Equity Research

Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.

AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?

by Zacks Equity Research

Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.

Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have registered solid product sales during Q2 which are likely to have driven its overall top line.

Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up

by Zacks Equity Research

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.

Henry Schein (HSIC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 16.84% and 2.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment is expected to have driven up Q3 sales.

Urmimala Biswas headshot

4 Medical Device Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.

Merit Medical (MMSI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is a Beat in the Cards for CVS Health (CVS) in Q2 Earnings?

by Zacks Equity Research

CVS Health's (CVS) consumer-centric digital approach to administer vaccines across the nation is expected to have strongly contributed to its Q2 performance within retail segment.

Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.

Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?

by Zacks Equity Research

Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.

What's in Store for Henry Schein (HSIC) in Q2 Earnings?

by Zacks Equity Research

Henry Schein's (HSIC) PPE sales from medical business are likely to have maintained momentum in Q2. Also, global recovery trends of its dental business are expected to reflect on Q2 results.

STERIS (STE) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.

What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) fiscal second-quarter top line is expected to have benefited from strength in CAG and LPD businesses.

Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning

by Zacks Equity Research

Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.

Breast Health Sales to Aid Hologic's (HOLX) Q3 Earnings

by Zacks Equity Research

The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.

What's in Store for Edwards Lifesciences (EW) Q2 Earnings?

by Zacks Equity Research

Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout

by Zacks Equity Research

PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued strength in the Global Healthcare and Life Sciences segment.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Continued adoption of Invisalign Clear Aligners and iTero scanners are expected to have contributed to the Align Technology's (ALGN) second-quarter 2021 results.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.